Phase Labs is building electrophysiological technology to regrow organs and limbs inside the human body

Summary

Phase Labs is building electrophysiological technology designed to regenerate organs and limbs inside the human body — no genetic engineering required.

The founding premise is that the same bioelectrical signals that govern brain activity are present throughout the body and encode the instructions that guided a single zygote to self-assemble into a functioning human. Research over the past 15 to 20 years has established that these electrophysiological signals control morphogenesis, the process by which organisms grow and take form. Phase Labs is attempting to learn that signaling language and modulate it to trigger regeneration in adults — a capacity the human body largely loses with age, even though infant humans can already regrow the tips of their fingers.

The company is explicitly not pursuing genetic engineering. The founder argues that identifying a handful of genes to correct the problem is unlikely to work, and that modifying physiological signals directly is both more scientifically sound and carries a cleaner regulatory profile.

Near-term vs. long-term roadmap

The long-term targets are limb regeneration and kidney regeneration, both framed as 10 to 15 year research programs. The kidney is described as anatomically more complex than a limb, making it the harder of the two.

In the near term, Phase Labs is focused on chronic wound healing, particularly in diabetic patients suffering from ulcers — currently the leading cause of amputations worldwide. The near-term approach uses a medical device framework rather than biologics, because medical devices move through FDA clinical trials significantly faster. The eventual product vision is a combination device that layers biophysical stimulation through light and ultrasound with the molecular specificity of proteins.

Scar tissue repair falls under the same electrophysiological mechanism. Existing electric wound dressings on the market can accelerate healing for stage one and stage two injuries up to roughly five millimeters, but complexity increases sharply once muscle and bone are involved.

Skepticism on xenotransplantation

The founder is skeptical of genetically edited pig organ transplants, pointing to unresolved questions around immune rejection and immunogenicity. The preferred alternative is inducing the body to grow its own replacement organ, which avoids the rejection problem entirely. The argument is that any durable solution to organ failure requires understanding and replicating the body's own regenerative code rather than introducing foreign biological material.

Longer horizon

If the underlying technology works at scale, the founder sees a plausible connection between full-body organ regeneration and longevity, potentially extending healthy human lifespans by 100 years. On the more speculative end, the same framework that governs biological regeneration could, in principle, be used to engineer artificial biological networks — living constructs, or biobots, analogous to artificial neural networks in AI. That is a long way from chronic wound healing, but it is where the underlying science points if the morphogenetic signaling language can be fully decoded.